Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 2

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 4Lymphoid 4Breast 4Sarcoma 2Gynecologic 2Genitourinary 2Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 3Mesothelioma 1Lung Neoplasms 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × MLN 8237 × Thoracic × Clear all
NCT06095505 2026-06-05

ALISCA-Lung1

Puma Biotechnology, Inc.

Phase 2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07465757 2026-03-12

ALISCA-Lung2

Puma Biotechnology, Inc.

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02293005 2022-10-04

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

M.D. Anderson Cancer Center

Phase 2 Completed
28 enrolled 11 charts
Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT02038647 2018-12-27

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Takeda

Phase 2 Completed
178 enrolled 27 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡